MPNs

The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.

The phase 2 RESTORE-PV trial is exploring the monoclonal antibody DISC-3405 in polycythemia vera across 2 dosing cohorts.

The application for the selinexor combination is supported by data from the phase 3 SENTRY trial.

The approval marks the first new agent specifically approved for essential thrombocythemia in the US in nearly 30 years.

The approval is primarily supported by the phase 3 VERIFY study.

During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk assessment for polycythemia vera.

ENHANCE phase 3 results show that magrolimab added to azacitidine failed to boost remission or survival in higher-risk MDS and increased serious toxicity.

During a live event, Kristen M. Pettit, MD, and participants discussed second-line considerations in high-risk polycythemia after hydroxyurea failure.

During a live event, Andrew Brunner, MD, and participants discussed second-line therapy selection in lower-risk MDS following ESA failure.

The T-cell immunotherapy Orca-T has gained FDA approval in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).

During a live event, Andrew Brunner, MD, and participants discussed escalating therapy in luspatercept-refractory LR-MDS.

FDA clears BESREMi Pen, adding a simpler self-injection choice for adults with polycythemia vera on long-term ropeginterferon therapy.

During a live event, Kristen M. Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course.

Ofirnoflast is a first-in-class oral allosteric modulator of NEK7 that previously received FDA orphan drug designation.

The combo did not, however, meet the coprimary end point of absolute change in total symptom score.

A sneak peek at the heme-onc abstracts at EHA 2026: CLL triplets, frontline menin inhibition, earlier myeloma bispecifics, and post‑JAK myelofibrosis combos poised to shift care.

"DISC-0974 treatment resulted in sustained hepcidin and serum iron, regardless of concomitant JAKi therapy or baseline transfusion requirement,” said Naseema Gangat, MBBS.

During a live event, Firas El Chaer, MD, highlighted pivotal data informing decision making in frontline polycythemia vera.

The results strengthen the evidence base for imetelstat's benefit in this high-risk, post-ruxolitinib myelofibrosis population.

Patients with high-risk myelodysplastic syndrome received the novel anti-IL1RAP antibody nadunolimab combined with azacitidine.

Long-term real-world safety and effectiveness of darbepoetin alfa in MDS-related anemia are consistent with registration trial findings.

Jakafi XR offers bioequivalent alternative to twice-daily formulation; pharmacy availability expected by May 8.

During a Case-Based Roundtable event, Thomas LeBlanc, MD, discussed risk stratification and the latest data regarding luspatercept and imetelstat for lower-risk MDS.

The monoclonal antibody LYT-200 demonstrated promising clinical activity and a favorable safety profile in patients with high-risk myelodysplastic syndrome.

The treatment landscape for high- and low-risk polycythemia vera is shifting with large scale studies such REVEAL and Low-PV changing practice.